3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
18
Non-Muscle Invasive Bladder Neoplasms
12
Carcinoma, Transitional Cell
11
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Anus Neoplasms
5
Lung Neoplasms
4
Neoplasms
3
Carcinoma, Hepatocellular
3
Carcinoma
3
Urologic Neoplasms
2
Urologic Diseases
2
Urogenital Neoplasms
2
Urinary Bladder Diseases
2
Stomach Neoplasms
2
Neoplasms by Site
2
Colonic Neoplasms
2
Anal Canal Carcinoma
2
Uterine Cervical Neoplasms
1
Urogenital Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Pseudomyxoma Peritonei
1
Pancreatic Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms, Squamous Cell
1
Neoplasm Recurrence, Local
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Mycobacterium Infections
1
Interventions
Magnetic Resonance Spectroscopy
3
Prednisone
2
Positron-Emission Tomography
2
Lenalidomide
2
Injections
2
Dexamethasone
2
Cyclophosphamide
2
technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid)
1
obinutuzumab
1
lortalamine
1
fluciclovine F-18
1
Vindesine
1
Vincristine
1
Transplantation, Autologous
1
Thalidomide
1
Rituximab
1
Mitomycin
1
Melphalan
1
Doxorubicin
1
Diagnosis
1
Bleomycin
1
3-Iodobenzylguanidine
1
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Disease
×
Mitomycin
×
Clear all
NCT03335059
2020-04-15
RITE-USA
Medical Enterprises Ltd.
Phase 3
Terminated
5 enrolled